Nasdaq · Healthcare
Monte Rosa Therapeutics, Inc. (GLUE)
As-reported financials and recent SEC filings for Monte Rosa Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$123.7M
Net income
$-38.6M
Net margin
-31.2%
Diluted EPS
—
ROE
-16.6%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $123.7M | $75.6M | $0 | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-54.2M | $-81.1M | $-143.3M | $-112.4M | $-72.9M |
| Net income | $-38.6M | $-72.7M | $-135.4M | $-108.5M | $-74.0M |
| Diluted EPS | — | — | — | — | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-06
View on EDGAR →SCHEDULE 13D/A2026-07-06
View on EDGAR →42026-07-01
View on EDGAR →1442026-06-30
View on EDGAR →42026-06-30
View on EDGAR →42026-06-30
View on EDGAR →1442026-06-29
View on EDGAR →1442026-06-29
View on EDGAR →Largest Healthcare peers
Go deeper on GLUE
Search Monte Rosa Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.